This feature is written using content from our recently published Liquid Biopsy report, which you can read in full by […]
Despite global recognition that diversity within population studies is poor, clinical trials for current treatments and vaccines for COVID-19 still […]
A new partnership deal struck between Q2 solutions, a clinical laboratory services organisation, and Thermo Fisher Scientific says it will […]
With a wealth of genomic technologies rapidly advancing with falling cost, implementing genomics into trials and routine care is becoming […]
Ahead of our virtual panel discussion on the promises and pitfalls of precision medicine trials: now and in the future […]
Last week, we wrote a blog post on the benefits of integrating genomics into clinical trials, such as improved methods […]
Genomics has the potential to improve efficacy of drugs and accelerate precision healthcare, but one area with the biggest potential […]
“No decision about me, without me” was to be the new standard of thinking for a more patient-centric NHS future, […]
Andrea Jorgensen is a Professor of Biostatistics at the University of Liverpool. She obtained an MSc with distinction in Medical […]
Liquid biopsy is rapidly transforming how cancer is detected, monitored, and treated. While major progress has been made in identifying tumour-derived signals in […]
